ORIGINAL RESEARCH article
Front. Oncol.
Sec. Genitourinary Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1615005
This article is part of the Research TopicRadiomics and Artificial Intelligence in Oncology ImagingView all 17 articles
Biparametric MRI-based Radiomics for Differentiating Clinically Significant Prostate Cancer Among Prostate-specific Antigen Level of Gray Zone
Provisionally accepted
- 1Yancheng First People's Hospital, Yancheng, Jiangsu, China
- 2Tinghu People's Hospital, Yancheng, China
- 3Jiangsu Medical College, Yancheng, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Purpose: This study was intended to evaluate the performance of biparametric MRI (bpMRI) radiomics for detecting clinically significant prostate cancer (csPCa) in men with prostate-specific antigen (PSA) of 4-10 ng/mL. Method: We retrospectively included 287 patients with PSA levels of 4-10 ng/mL. Radiomics features were extracted from two MRI protocols of T2-weighted imaging (T2WI) and diffusion-weighted imaging (DWI, with b-values of 0, 1000, and 2000 s/mm ² ), and then selected with the least absolute shrinkage and selection operator (LASSO) regression method. The apparent diffusion coefficient (ADC) maps were calculated from these images and used for analysis. The radiomics signature (Radscore) based on the most useful radiomics features was calculated with the logistic regression method. MRI/US fusion targeted biopsy results were used as the reference standard. Diagnostic performance was decided using the area under the receiver operating characteristic (ROC) curve (AUC), and compared with Delong's test. Finally, a model integrating radiomics features and Prostate Imaging Reporting and Data System (PI-RADS) was constructed. Results: A total of 15 T2WI radiomics features and 12 from DWI features were retained after selection with LASSO regression. On the test set, radiomics outperformed PI-RADS, with an AUC of 0.928 (95% CI 0.868-0.988) vs. 0.807 (95% CI 0.705-0.908; P=0.04). Additionally, the combined nomogram generated higher diagnostic accuracy (AUC 0.955, 95% CI 0.905-1.00), significantly outperforming both PI-RADS (P=0.002) and radiomics alone (P=0.02). Conclusion: bpMRI-based radiomics exhibited promising diagnostic accuracy for the detection of csPCa, significantly outperforming either PI-RADS or PSAD among patients with PSA of 4-10 ng/mL. Furthermore, the developed nomogram integrating radiomics and PI-RADS could further enhance diagnostic performance.
Keywords: bpMRI, prostate cancer, PI-RADS, Radiomics, Diagnostic performance
Received: 20 Apr 2025; Accepted: 06 Aug 2025.
Copyright: © 2025 Ji, Liu, Liu and Wen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Jing Wen, Jiangsu Medical College, Yancheng, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.